{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cruz LR"],"funding":["British Embassy Havana"],"pagination":["206-212"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7755077"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["4(1)"],"pubmed_abstract":["The instrumental role of CK2 in the SARS-CoV-2 infection has pointed out this protein kinase as promising therapeutic target in COVID-19. Anti-SARS-CoV-2 activity has been reported by CK2 inhibitors <i>in vitro</i>; however, no anti-CK2 clinical approach has been investigated in COVID-19. This trial aimed to explore the safety and putative clinical benefit of CIGB-325, an anti-CK2 peptide previously assessed in cancer patients. A monocentric, controlled, and therapeutic exploratory trial of intravenous CIGB-325 in adults hospitalized with COVID-19 was performed. Twenty patients were randomly assigned to receive CIGB-325 (2.5 mg/kg/day during 5-consecutive days) plus standard-of-care (10 patients) or standard-of-care alone (10 patients). Adverse events were classified by the WHO Adverse Rea"],"journal":["ACS pharmacology & translational science"],"pubmed_title":["Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial."],"pmcid":["PMC7755077"],"funding_grant_id":["CIGB-300/2020"],"pubmed_authors":["Cruz LR","ATENEA-Co-300 Group","Torres L","Muzio V","Valenzuela C","Chacon D","Perea SE","Thompson D","Diaz PA","Guillen G","Reyes R","Baladron I","Perera G","Perez J","Rosales M","Perez GV","Rodriguez R","Ramon AC","Vazquez MM","Valido Y","Perera Y","Garcia A","Santana R","Vazquez-Bloomquist DM","Rittoles A","Gonzalez A"],"additional_accession":[]},"is_claimable":false,"name":"Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial.","description":"The instrumental role of CK2 in the SARS-CoV-2 infection has pointed out this protein kinase as promising therapeutic target in COVID-19. Anti-SARS-CoV-2 activity has been reported by CK2 inhibitors <i>in vitro</i>; however, no anti-CK2 clinical approach has been investigated in COVID-19. This trial aimed to explore the safety and putative clinical benefit of CIGB-325, an anti-CK2 peptide previously assessed in cancer patients. A monocentric, controlled, and therapeutic exploratory trial of intravenous CIGB-325 in adults hospitalized with COVID-19 was performed. Twenty patients were randomly assigned to receive CIGB-325 (2.5 mg/kg/day during 5-consecutive days) plus standard-of-care (10 patients) or standard-of-care alone (10 patients). Adverse events were classified by the WHO Adverse Rea","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Feb","modification":"2026-05-08T15:13:58.071Z","creation":"2021-02-25T08:54:52Z"},"accession":"S-EPMC7755077","cross_references":{"pubmed":["33615173"],"doi":["10.1021/acsptsci.0c00175"]}}